Withheld: gross profit could not be reconciled with the rest of this filer’s statement.
Bausch Health Companies Inc. (BHC) reported revenue of $10.27B and net income of $157.00M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Bausch Health Companies Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.27B | $9.62B | $8.76B | $8.12B | $8.43B | $8.03B | $8.60B | $8.38B | $8.72B | $9.67B |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $2.51B | $2.57B |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | $1.81B | $1.55B | $963.00M | $454.00M | $450.00M | $676.00M | -$203.00M | -$2.38B | $102.00M | -$566.00M |
| Net income | $157.00M | -$46.00M | -$592.00M | -$225.00M | -$948.00M | -$560.00M | -$1.79B | Unavailable | Unavailable | Unavailable |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 375.00M | shares 368.00M | shares 364.90M | shares 362.00M | shares 358.90M | shares 355.00M | shares 352.10M | shares 351.30M | shares 351.80M | shares 347.30M |
| Pretax income | $367.00M | $167.00M | -$390.00M | -$129.00M | -$1.02B | -$934.00M | -$1.84B | -$4.15B | -$1.74B | -$2.44B |
| Income tax expense | $247.00M | $239.00M | $221.00M | $83.00M | -$87.00M | -$375.00M | -$54.00M | -$10.00M | -$4.14B | -$27.00M |
| Diluted EPS | $0.42 | $-0.13 | $-1.62 | $-0.62 | $-2.64 | $-1.58 | $-5.08 | $-11.81 | $6.83 | $-6.94 |
| Selling, general & administrative | $3.44B | $3.30B | $2.92B | $2.62B | $2.62B | $2.37B | $2.55B | $2.47B | $2.58B | $2.81B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.31B | $1.18B | $947.00M | $564.00M | $582.00M | $605.00M | $3.24B | $721.00M | $720.00M | $542.00M |
| Total assets | $26.37B | $26.52B | $27.35B | $25.69B | $29.20B | $31.20B | $33.86B | $32.49B | $37.50B | $43.53B |
| Current assets | $6.16B | $5.77B | $5.60B | $4.25B | $5.61B | $5.34B | $6.97B | $4.21B | $4.75B | $5.08B |
| Total liabilities | $25.99B | $26.84B | $27.43B | $25.43B | $29.24B | $30.59B | $32.73B | $29.68B | $31.55B | $40.27B |
| Current liabilities | $4.18B | $6.75B | $4.30B | $3.94B | $5.20B | $4.91B | $6.25B | $3.84B | $4.27B | $3.61B |
| Total equity incl. NCI | $377.00M | -$322.00M | -$82.00M | $260.00M | -$34.00M | $605.00M | $1.14B | $2.82B | $5.94B | $3.26B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $1.63B | $1.60B | $1.54B | $1.09B | $993.00M | $1.09B | $1.11B | $934.00M | $1.05B | $1.06B |
| Accounts receivable | $2.35B | $2.14B | $2.00B | $1.79B | $1.78B | $1.58B | $1.84B | $1.86B | $2.13B | $2.52B |
| Goodwill | $11.27B | $11.09B | $11.18B | $11.55B | $12.46B | $13.04B | $13.13B | $13.14B | $15.59B | $15.79B |
| Long-term debt | $20.59B | $18.94B | $21.94B | $20.33B | $22.65B | $23.92B | $24.66B | $24.08B | $25.24B | $29.84B |
| Accounts payable | $600.00M | $589.00M | $719.00M | $521.00M | $407.00M | $337.00M | $503.00M | $411.00M | $365.00M | $324.00M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.40B | $1.60B | $1.03B | -$728.00M | $1.43B | $1.11B | $1.50B | $1.50B | $2.29B | $2.09B |
| Capital expenditures | $397.00M | $337.00M | $215.00M | $218.00M | $269.00M | $302.00M | $270.00M | $157.00M | $171.00M | $235.00M |
| Investing cash flow | -$595.00M | -$454.00M | -$2.14B | -$303.00M | $409.00M | -$261.00M | -$419.00M | -$196.00M | $2.89B | -$125.00M |
| Financing cash flow | -$742.00M | -$868.00M | $1.48B | -$474.00M | -$1.51B | -$2.29B | $1.44B | -$1.35B | -$4.96B | -$1.96B |
| Net change in cash | $124.00M | $239.00M | $371.00M | -$1.53B | $303.00M | -$1.43B | $2.52B | -$74.00M | $255.00M | -$55.00M |
| Stock-based compensation | $216.00M | $150.00M | $132.00M | $126.00M | $128.00M | $105.00M | $102.00M | $87.00M | $87.00M | $165.00M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $0 | $0 |
| Depreciation & amortization | $1.21B | $1.27B | $1.26B | $1.39B | $1.55B | $1.82B | $2.08B | $2.82B | $2.86B | $2.87B |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $1.00B | $1.26B | $817.00M | -$946.00M | $1.16B | $809.00M | $1.23B | $1.34B | $2.12B | $1.85B |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | 17.7% | 16.1% | 11.0% | 5.6% | 5.3% | 8.4% | -2.4% | -28.4% | 1.2% | -5.9% |
| FCF margin | 9.8% | 13.1% | 9.3% | -11.6% | 13.7% | 10.1% | 14.3% | 16.0% | 24.3% | 19.1% |
| SBC / revenue | 2.1% | 1.6% | 1.5% | 1.6% | 1.5% | 1.3% | 1.2% | 1.0% | 1.0% | 1.7% |
| Current ratio | 1.47x | 0.86x | 1.30x | 1.08x | 1.08x | 1.09x | 1.12x | 1.10x | 1.11x | 1.41x |
| Revenue YoY growth | 6.7% | 9.9% | 7.8% | -3.7% | 5.1% | -6.7% | 2.6% | -3.9% | -9.8% | Unavailable |
| Net margin | 1.5% | -0.5% | -6.8% | -2.8% | -11.2% | -7.0% | -20.8% | Unavailable | Unavailable | Unavailable |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 3.9% | 3.5% | 2.5% | 2.7% | 3.2% | 3.8% | 3.1% | 1.9% | 2.0% | 2.4% |
| Long-term debt / equity | 54.62x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 67.3% | 143.1% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BHC in the interactive workspace to inspect any figure back to its filing.
Source filings
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
Withheld: gross profit could not be reconciled with the rest of this filer’s statement.